Experimental evaluation of efficacy of a HIV filter

doi:10.16150/j.1671-2870.2019.06.014

Abstract

Abstract:

Objective: To test the efficacy of a disposable membrane filter for the elimination of HIV. Methods: A total of 10 plasma samples were tested in this study. Plasma samples containing HIV were pressurizedly filtered through the filter. Copies of HIV RNA in the plasma before and after filtration were counted to calculate the efficacy of the filter. Results: The average HIV clearance rate of the filter was 96.62%. There was significant difference in number of HIV RNA copies before and after filtration (P=0.001). However, linear relationship was not seen between the clearance rate and the initial number of HIV RNA copies (P=0.924 2). Conclusions: The HIV clearance rate of this disposable membrane filter is high, and it might be feasible to eliminate the HIV virus by physical adsorption.

Key words: Human immunodeficiency virus, Filtration membrane, Clearance rate

CLC Number:

R512.91

ZHANG Lin, ZHOU Ying, LI Haicong, SUN Meiyan, SUN Wenxiu, LU Lingqing, ZHU Zhaoqin, TANG Qi, ZHANG Renfang, SHEN Yinzhong, LU Hongzhou. Experimental evaluation of efficacy of a HIV filter[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 676-679.

Figures/Tables 4

References 11

[1]	UNAIDS.Data 2019[DB].https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data
[2]	疾病预防控制局.2018年12月全国法定传染病疫情概况[EB/OL]. (2019-01-17)[2019-12-25].http://www.nhfpc.gov.cn/jkj/s3578/new_list.shtml.
[3]	中国疾病预防控制中心, 性病艾滋病预防控制中心, 性病控制中心. 2018年第3季度全国艾滋病性病疫情[J]. 中国艾滋病性病, 2018, 24(11):1075.
[4]	韩孟杰. 2018年全国HIV的疫情概况[C]// 中国疾病预防控制中心.北京, 2018.
[5]	Neupane S, Dhungana GP, Ghimire HC. Adherence to antiretroviral treatment and associated factors among people living with HIV and AIDS in CHITWAN, Nepal[J]. BMC Public Health, 2019, 19(1):720. doi: 10.1186/s12889-019-7051-3 pmid: 31182074
[6]	Dupont E, Yombi JC. Is antiretroviral two-drug regimen the new standard for HIV treatment in naive patients?[J]. AIDS Rev, 2019, 21(3):143-156.
[7]	张智远, 宁少萍. 艾滋病抗病毒治疗595例药物毒副反应分析[J]. 基层医学论坛, 2014, 18(29):4004-4005.
[8]	Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions[J]. J Antimicrob Chemother, 2011, 66(9):2107-2111 doi: 10.1093/jac/dkr248 pmid: 21680580
[9]	Morowatisharifabad MA, Movahed E, Farokhzadian J, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV/AIDS: a case study in Iran[J]. BMC Res Notes, 2019, 12(1):162 doi: 10.1186/s13104-019-4204-5 pmid: 30902063
[10]	张晓伟, 刘志斌, 郭会军. 服药依从性对HAART的艾滋病病人血浆药物浓度及免疫功能和病毒载量的影响[J]. 中国艾滋病性病, 2016, 22(11):850-852.
[11]	Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral the-rapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy[J]. AIDS, 2009, 23(9):1127-1134. doi: 10.1097/QAD.0b013e32832ac34e pmid: 19417582

数值	过滤前HIV含量(拷贝/mL)	过滤后HIV含量(拷贝/mL)	过滤前后HIV含量差(拷贝/mL)	滤除率（%）
观测次数	10	10	10	-
中位数	44 100(37 125, 67 350)	1 810(833, 2 463)	42 805(36 102,64 960)	96.62(96.28,97.95)
最小值,最大值	35 900, 69 100	642, 2 520	33 380, 66 628	92.98, 98.22

样本	过滤前HIV含量（拷贝/mL）	过滤后HIV含量（拷贝/mL）	滤除率（%）
1	69 100	2 472	96.42
2	67 000	2 460	96.33
3	41 400	861	97.92
4	68 400	2 180	96.81
5	50 000	1 890	96.22
6	35 900	2 520	92.98
7	46 800	1 730	96.30
8	36 000	642	98.22
9	37 500	1 150	96.93
10	38 800	749	98.06

[1]	SHI Xia, MA Xin, WANG Zhenyan, ZHANG Hui, LIU Shaojun. Analysis on the clinicopathological characteristics and follow-up of 32 patients with human immunodeficiency virus infection and chronic kidney diseases [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 437-443.
[2]	HU Jingjing, LÜ Haiwei, XUN Jingna, SHEN Yinzhong, LIU Li, LU Hongzhou. Characteristcs of mycobacterial species distribution in acquired immunodeficiency syndrome patients with mycobacterial infection in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 450-455.
[3]	CHEN Hong, SHEN Yinzhong. Progress in diagnosis and treatment of human immunodeficiency virus infection/acquired immune deficiency syndrome complicated with tuberculosis [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 530-534.
[4]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(02): 180-184.
[5]	. [J]. Journal of Diagnostics Concepts & Practice, 2015, 14(06): 560-564.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2013, 12(05): 553-555.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2012, 11(03): 278-282.
[8]	. [J]. Journal of Diagnostics Concepts & Practice, 2011, 10(05): 440-443.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2011, 10(02): 133-137.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2008, 7(05): 511-516.
[11]	. [J]. Journal of Diagnostics Concepts & Practice, 2008, 7(02): 168-171.
[12]	. [J]. Journal of Diagnostics Concepts & Practice, 2007, 6(03): 210-212.